SOUTH EASTON, Mass., Sept. 11 /PRNewswire-FirstCall/ -- Pressure
BioSciences, Inc. (Nasdaq: PBIO) ("PBI" or "the Company") today announced
that it has entered into a Cooperative Research and Development Agreement
(CRADA) with the United States Army Medical Research Institute of
Infectious Diseases (USAMRIID). Researchers at USAMRIID have recently shown
that the use of the Company's patented pressure cycling technology ("PCT")
with patent-pending chemical reagents ("ProteoSolve-SB") has resulted in
the simultaneous decontamination and extraction of macromolecules (DNA,
RNA, proteins, lipids) as well as small molecules from samples containing
infectious pathogens. The purpose of this CRADA is to adapt PCT into
protocols for the development of medical countermeasures against dangerous
pathogens that endanger the warfighter. The CRADA will allow scientists
from PBI and USAMRIID to combine resources, experiences, and expertise to
help achieve this important goal.

Dr. Chunquin Li, Applications Scientist for Pressure BioSciences, said:
"The decontamination and extraction of biomolecules from samples containing
dangerous infectious pathogens for subsequent analysis is essential to the
development of improved therapies, vaccines, and diagnostics needed to
protect soldiers, emergency responders, and others against possible
exposure to biological threat agents."

Dr. Nathan Lawrence, Vice President of Marketing at PBI commented:
"Research on dangerous pathogens takes place within specially engineered
BioSafety Level (BSL) -3 or -4 suites. A rapid procedure to completely
decontaminate macromolecules enables the transfer of samples out of
containment suites where further studies are more easily conducted. While
traditional methods for decontamination have been proven safe, they often
render biological samples unsuitable for modern, state-of-the-art
biomolecular analysis. Researchers at USAMRIID have demonstrated that PCT
coupled with ProteoSolve-SB can kill infectious agents, without significant
adverse effects on the subsequent testing and analysis of macromolecules.
This was an important advancement, since some macromolecular assays cannot
be readily performed in BSL containment. These findings warranted further
testing."

Mr. Richard T. Schumacher, Founder, President, and CEO of Pressure
BioSciences, said: "We believe that data generated under the CRADA could
significantly accelerate and enhance current research studies involving
infectious or dangerous agents. Such improvements could be of great
importance to USAMRIID investigators, as well as to all scientists, whether
military or in the public or private sector, who are working to develop
more effective tools to counter bioterrorism. In addition, the knowledge
gained from research performed under this CRADA may be of great importance
to the many laboratories around the world working on the development of
improved medical protections - including diagnostics, therapeutics, and
vaccines - against infectious diseases not related to biological threat
agents."

CRADA Costs

PBI will support the CRADA by offering USAMRIID the use of a Barocycler
NEP3229 for a mutually agreed upon period of evaluation; by supplying
consumable processing containers (PULSE Tubes) and kits to USAMRIID; and by
the efforts of up to eight hours per week of technical support from PBI
scientists. All of these items will be offered at no charge. Conversely,
USAMRIID will support the CRADA through the technical support of its
scientific staff available for both containment and non-containment work.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused
on the development of a novel, enabling technology called Pressure Cycling
Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient
and ultra-high levels (up to 35,000 psi and greater) to control
bio-molecular interactions. PBI currently holds 13 US and 6 foreign patents
covering multiple applications of PCT in the life sciences field, including
such areas as genomic and proteomic sample preparation, pathogen
inactivation, the control of chemical reactions, immunodiagnostics, and
protein purification. Visit us at our website: http://www.pressurebiosciences.com.

About USAMRIID

USAMRIID, located at Fort Detrick, Maryland, is the lead medical
research laboratory for the U.S. Biological Defense Research Program, and
plays a key role in national defense and in infectious disease research.
The Institute conducts basic and applied research on biological threats
resulting in medical solutions (such as vaccines, drugs and diagnostics) to
protect the warfighter. While USAMRIID's primary mission is focused on the
military, its research often has applications that benefit society as a
whole. USAMRIID is a subordinate laboratory of the U.S. Army Medical
Research and Materiel Command. For more information, visit
http://www.usamriid.army.mil.

Forward Looking Statements

Statements contained in this press release regarding the Company's
intentions, hopes, beliefs, expectations, or predictions of the future are
"forward-looking" statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements include the reported
ability of PCT and ProteoSolve-SB to simultaneously decontaminate and
extract biomolecules from samples containing highly infectious agents; the
possibility that this new approach may be used in developing advanced
medical countermeasures against dangerous infectious diseases; that PCT may
enhance studies with infectious and dangerous materials; that PCT could
generate samples from highly infectious materials that can be analyzed
safely outside of the BSL-3 or -4 containment suites; that the work done
under the CRADA could lead to a better understanding of host response to
infectious agents and to improved diagnostics, medical therapies, and
vaccines; and that the data that may be generated under the CRADA could be
of importance to USAMRIID, other military and public and private
laboratories working in counter- bioterrorism, and other laboratories
around the world that are working to develop improved therapeutics and
diagnostics for infectious diseases not related to bioterrorism. These
statements are based upon the Company's current expectations, forecasts,
and assumptions that are subject to risks, uncertainties, and other factors
that could cause actual outcomes and results to differ materially from
those indicated by these forward-looking statements. These risks,
uncertainties, and other factors include, but are not limited to:
unforeseen technological difficulties that the Company may encounter in the
development of PCT and related chemistries, such as ProteoSolve-SB; the
possibility that due to the nature of the research being performed,
USAMRIID, as well as other laboratories, may not be able to replicate the
preliminary results reported and may not find the use of PCT and related
chemistries to be as advantageous as initially reported; that due to
competitive products, services, and technological advances, PCT may not be
the preferred method to simultaneously decontaminate and extract
biomolecules from materials containing highly infectious agents; and the
other risks and uncertainties discussed under the heading "Risk Factors" in
the Company's Annual Report on Form 10-K for the year ended December 31,
2007, and other reports filed by the Company from time to time with the
SEC. The Company undertakes no obligation to update any information
included in this release, except as otherwise required by law.

The information contained in this press release does not necessarily
reflect the position or the policy of the Government and no official
endorsement should be inferred.

(Date:12/8/2016)... ... December 08, 2016 , ... ... business of innovation is taking over sports. On Thursday, December 15th a panel ... technology is disrupting the playing field at a Smart Talk session. Smart Talk ...

(Date:12/8/2016)... N.J. , Dec. 8, 2016 Soligenix, ... biopharmaceutical company focused on developing and commercializing products to ... need, announced today that it will be hosting an ... am ET on the origins of innate defense regulators ... a review of oral mucositis and the recently announced ...